Medicine for promoting skin injury repair and healing and preparation method thereof

Abstract

The invention relates to a medicine for promoting skin injury repair and healing and a preparation method thereof, and belongs to the technical field of biological medicines.The medicine is prepared from a radix astragali preparata extract, lipidosome encapsulated panax notoginseng total saponin-RGD peptide, a honeysuckle flower-maca extract, an asiaticoside-hydroxypropyl-beta-cyclodextrin inclusion compound and dipotassium glycyrrhizinate; the radix astragali preparata extract is a product obtained by moistening radix astragali with honey, baking, extracting with deionized water, and adsorbing and purifying with a Sephadex G-15 column; the honeysuckle-maca extract is a product obtained by mixing dry honeysuckle powder and dry maca root powder according to the mass ratio of (3-5): (1-1.7), performing enzymolysis through cellulase, then performing common enzymolysis through ficin protease and papain, and performing adsorption and purification through an HPD722 macroporous adsorption resin column. All the components are compatible according to a specific proportion, so that the allergy and skin irritation risks are reduced, skin injury healing is reasonably promoted, and melanin deposition is effectively inhibited.

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a medicine for promoting the repair and healing of skin damage and a preparation method thereof. Background Art

[0002] Traditional Chinese medicine topical compresses have a long history of use in skin damage repair. Based on the TCM theory of "promoting blood circulation, removing blood stasis, promoting tissue regeneration, and healing sores," they modulate the wound microenvironment through the synergistic effects of their ingredients, demonstrating unique advantages in treating trauma, ulcers, burns, and other conditions. However, with advancements in medical technology, traditional, crude traditional Chinese medicine ointments still have shortcomings in terms of safety, effectiveness, and melanin control, as detailed below.

[0003] Allergic reactions are common and complex: Traditional Chinese medicine topical compresses contain a wide variety of ingredients, including plant proteins, volatile oils, alkaloids, and other allergens. Resins from frankincense and myrrh, and terpenoids from rosin, are common allergens. Traditional ointments containing these ingredients can cause local allergic reactions in 10%-20% of cases, manifesting as erythema, papules, blisters, and even contact dermatitis, with a higher incidence in those with allergies. Of particular concern is that some compound prescriptions, due to improper preparation of the medicinal ingredients (e.g., incomplete detoxification of aconite root), can cause acute irritation reactions such as local burning, redness, and swelling, requiring discontinuation of treatment in severe cases.

[0004] The safety of drug combinations lacks scientific validation: Traditional formulas often adhere to the "monarch, minister, assistant, and envoy" theory, but modern research confirms that some classic combinations carry potential risks. For example, while combining angelica and salvia miltiorrhiza can enhance blood circulation, both contain coumarins, which may competitively inhibit liver metabolic enzymes and lead to abnormally elevated local drug concentrations. While combining honeysuckle and scutellaria baicalensis can enhance anti-inflammatory effects, their tannins may combine to form insoluble complexes, reducing efficacy and increasing the risk of skin irritation. Currently, the safety thresholds for most formula combinations remain poorly studied.

[0005] Slow onset of effect and low response rate for complex wounds: Traditional Chinese medicine topical applications rely on the synergistic regulation of multiple ingredients, but their efficiency in repairing complex wounds, such as those caused by ischemia and infection, is significantly lower than that of Western medicine. The wound shrinkage rate of traditional Chinese medicine ointments alone is slower than that achieved with combined treatment with recombinant human vascular endothelial growth factor (rhVEGF). Due to the low bioavailability of the active ingredients of traditional Chinese medicine (such as astragalus polysaccharides and tanshinone), they are unable to rapidly initiate key repair processes such as angiogenesis and epithelial cell migration.

[0006] Poor control of melanin deposition: Some traditional Chinese medicines (such as psoralea corylifolia, angelica dahurica, and angelica pubescens) contain furanocoumarins, which can bind to tyrosinase in melanocytes, increasing their sensitivity to ultraviolet light and leading to localized hyperpigmentation. The blood-activating components of some herbs (such as Chuanxiong rhizome and safflower) may prolong the local inflammatory response window, prompting macrophages to release melanin-stimulating factors (such as stem cell factor (SCF)). This can lead to hyperpigmentation on wound surfaces. Existing research and development of topical Chinese medicines focuses primarily on promoting healing, with insufficient attention paid to regulating melanin metabolism. Although some studies have found that asiaticoside and baicalin have some anti-melanin effects, these effects are often offset in complex formulas due to inappropriate combinations (such as with psoralea corylifolia), making it difficult to achieve a synergistic "healing-promoting and anti-pigmentation" effect.

[0007] Therefore, topical medicines still need to be improved in terms of safety, high bioavailability, and anti-pigmentation, and optimize ingredient extraction and ratios to achieve the triple goals of "safety-efficient healing-low pigmentation" to better meet the quality requirements of repair. Summary of the Invention

[0008] The existing Chinese herbal topical medicines for repairing skin damage still have shortcomings in terms of safety, efficiency and pigmentation control. The present invention provides a medicine for promoting the repair and healing of skin damage and a preparation method thereof. A special method is used to prepare roasted astragalus extract, liposome-encapsulated Panax notoginseng total saponin-RGD peptide, and honeysuckle-maca extract, which are combined with Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion compound and dipotassium glycyrrhizate in a specific proportion, thereby comprehensively solving the problems of traditional Chinese herbal topical medicines in terms of safety, therapeutic effect and control of skin pigmentation. By removing impurities that cause allergies, the comprehensive effects of reducing the risk of allergies and skin irritation, efficiently promoting the healing of skin damage, and effectively inhibiting melanin deposition are achieved, effectively improving the efficacy of "safety, efficient healing, and low pigmentation". The specific technical scheme is as follows: A drug for promoting the repair and healing of skin damage, comprising the following raw materials in parts by mass: 25 to 30 parts of roasted astragalus root extract, 11 to 15 parts of liposome-encapsulated Panax notoginseng total saponin-RGD peptide, 12 to 15 parts of honeysuckle-maca extract, 6 to 10 parts of asiaticoside-hydroxypropyl-β-cyclodextrin inclusion compound, and 3 to 5 parts of dipotassium glycyrrhizate; the roasted astragalus root extract is prepared by moistening astragalus root with honey, baking, extracting with deionized water, and filtering with Sephadex. The roasted Astragalus root extract was purified by G-15 column adsorption; in the liposome-encapsulated Panax notoginseng total saponins-RGD peptide, the mass ratio of Panax notoginseng total saponins to RGD peptide was (8-10): (3-5); the honeysuckle-maca extract was prepared by mixing honeysuckle dry powder and maca root dry powder in a mass ratio of (3-5): (1-1.7), hydrolyzing with cellulase, and then co-hydrolyzing with ficin and papain, and then purified by adsorption on an HPD722 macroporous adsorption resin column.

[0009] The preparation method of the above-mentioned roasted astragalus extract includes: slicing astragalus, moistening it with honey at a honey-drug mass ratio of (0.2-0.3):1, baking it, crushing it, adding deionized water at a material-liquid mass ratio of 1:(12-15), extracting it at 90°C-95°C, filtering to obtain a filtrate, concentrating it under reduced pressure to 20%-30% of the volume of the filtrate, adding ethanol to a final volume concentration of 65%-70%, standing it, centrifuging it, taking the supernatant, concentrating it under reduced pressure to 10%-15% of the volume of the supernatant, loading it onto a Sephadex G-15 column, eluting it with a 15%-20% volume concentration ethanol aqueous solution for 2BV-3BV to remove impurities, eluting it with a 50%-70% volume concentration ethanol aqueous solution for 3BV-4BV, collecting the eluate, concentrating it under reduced pressure to remove ethanol, and freeze-drying it to obtain the roasted astragalus extract.

[0010] In the preparation method of the above-mentioned roasted astragalus extract, the honey soaking time is 2h~3h; the baking is at 90℃~100℃ for 15min~25min; the crushed particle size is passed through a 40-mesh to 60-mesh sieve; the extraction time is 2h~3h; the standing temperature is 4℃~6℃ for 24h~30h; the centrifugation is at 8000rpm~9000rpm for 15min~20min; the pH value of the 50%~70% volume concentration ethanol aqueous solution is adjusted to 5.0~5.5 with acetic acid; and the temperature of the reduced pressure concentration is 60℃~65℃.

[0011] The preparation method of the liposome-encapsulated Panax notoginseng total saponin-RGD peptide includes: preparing a solute according to a mass ratio of soybean lecithin: cholesterol = (4-5): (1-1.5), dissolving it in anhydrous ethanol to a solute concentration of 45 mg / mL-50 mg / mL to obtain an organic phase; adding a mixture of Panax notoginseng total saponins and RGD peptide according to a mass ratio of (8-10): (3-5) to a phosphate buffer solution to a concentration of 15 mg / mL-20 mg / mL to obtain an aqueous phase; injecting the organic phase into the aqueous phase according to a volume ratio of organic phase: aqueous phase = 1: (1-1.5), stirring, rotary evaporation to remove ethanol, obtaining a concentrated solution, probe sonication, adding trehalose, and freeze-drying to obtain liposome-encapsulated Panax notoginseng total saponin-RGD peptide.

[0012] In the preparation method of the liposome-encapsulated Panax notoginseng total saponin-RGD peptide, the pH of the phosphate buffer solution is 7.4-7.6; the organic phase is injected into the aqueous phase at 55°C-60°C; the stirring is at 600rpm-800rpm for 30min-50min; the rotary evaporation temperature is 55°C-60°C; the probe ultrasound is 200W-250W probe ultrasound for 8min-12min, and the average particle size is controlled below 120nm; the amount of trehalose added is trehalose to a final concentration of 5wt%-8wt% of the concentrated solution.

[0013] The preparation method of the honeysuckle-maca extract comprises the following steps: mixing honeysuckle dry powder and maca root dry powder according to a mass ratio of (3-5):(1-1.7) to obtain mixed powder; adding deionized water, adjusting pH to 5.0-5.5 by acetic acid, adding cellulase, and carrying out enzymolysis at 55-60 DEG C for 2-3 hours; adjusting pH to 6.5-7.0 by dilute alkali, adding ficin and papain, and carrying out enzymolysis at 55-60 DEG C for 2-3 hours; heating extraction, centrifugation, obtaining supernatant, concentrating to 20-30% of the volume of the supernatant under reduced pressure to obtain concentrated solution, loading onto an HPD722 macroporous adsorption resin column, washing impurities with 2-3 BV of water, washing impurities with 1-2 BV of 30-35% volume concentration ethanol aqueous solution, eluting with 3-5 BV of 60-65% volume concentration ethanol aqueous solution, collecting eluate, removing ethanol under reduced pressure, and freeze-drying to obtain the honeysuckle-maca extract.

[0014] In the preparation method of the honeysuckle-maca extract, the particle size of the honeysuckle dry powder and the maca root dry powder is 40-60 mesh; the amount of the deionized water is 8-12 times the mass of the mixed powder; the amount of the cellulase added is 0.5-1% of the mass of the mixed powder; the amount of the ficin and the papain added is 0.5-1% of the mass of the mixed powder; the heating extraction is carried out at 80-85 DEG C for 2-3 hours; the centrifugation is carried out at 8000-9000 rpm for 15-20 minutes; and the temperature of the concentration under reduced pressure is 60-65 DEG C.

[0015] The preparation method of the asiaticoside-hydroxypropyl-β-cyclodextrin inclusion compound comprises the following steps: mixing asiaticoside and hydroxypropyl-β-cyclodextrin according to a mass ratio of 1:(2-2.5) to prepare a mixture, dissolving the mixture in ethanol aqueous solution to a concentration of 10-15 mg / mL, probe ultrasonic treatment, cold storage, and freeze-drying to obtain the asiaticoside-hydroxypropyl-β-cyclodextrin inclusion compound.

[0016] In the preparation method of the asiaticoside-hydroxypropyl-β-cyclodextrin inclusion compound, the ethanol aqueous solution is 30-35% volume concentration ethanol aqueous solution; the probe ultrasonic treatment is carried out at 20-25 DEG C and 350-400 W for 40-60 minutes; and the cold storage is carried out at 4-6 DEG C for 12-16 hours.

[0017] The preparation method of the medicine for promoting skin damage repair and healing comprises the following steps: uniformly mixing raddeanin extract, liposome-encapsulated panax notoginseng total saponins-RGD peptide, honeysuckle-maca extract, asiaticoside-hydroxypropyl-β-cyclodextrin inclusion compound, and dipotassium glycyrrhizinate according to mass parts to obtain a mixed medicine.

[0018] The mixed drug prepared above is mixed with pharmaceutically acceptable excipients to obtain a dressing for promoting the repair and healing of skin injuries.

[0019] The present invention provides a drug for promoting the repair and healing of skin damage and a preparation method thereof, and the beneficial effects include: First, through its scientific ingredient combination and rigorous preparation process, this drug comprehensively addresses the challenges of traditional Chinese medicine topical application in terms of safety, therapeutic efficacy, and skin pigmentation control. By removing impurities that cause allergies, it achieves the combined effects of reducing the risk of allergies and skin irritation, effectively promoting the healing of skin injuries, and effectively inhibiting melanin deposition, effectively enhancing the efficacy of "safety, efficient healing, and low pigmentation."

[0020] Second, the astragalus root is first moistened with honey. This process not only corrects the flavor of the medicine but also enhances the extraction efficiency and efficacy. The subsequent roasting and processing process transforms the astragalus root's internal components, enhancing its stability and effectiveness. During the extraction process, specific temperature and time control are used to fully dissolve the active ingredients in the astragalus root. Then, purification is performed using a Sephadex G-15 column, utilizing its molecular sieve principle to effectively remove allergenic impurities while retaining components that enhance red blood cell membrane stability. This series of precisely controlled parameters ensures the high purity and stable activity of the extracted ingredients, greatly improving the safety of the medication.

[0021] 3. Liposome encapsulation of Panax notoginseng saponins-RGD peptide When constructing liposome carriers, they are mixed in a specific ratio to form a stable phospholipid bilayer structure. This structure is like a miniature protective film that encapsulates Panax notoginseng saponins and RGD peptides, isolates immune cells, effectively avoids triggering immune responses, and delays the degradation of RGD peptides when used on the skin. During the preparation process, probe ultrasound is used to control the liposome particle size and improve absorption. The sustained-release properties of liposomes enable Panax notoginseng saponins-RGD peptides to be released continuously and slowly, providing a stable and lasting signal for cell proliferation, promoting cell division and growth.

[0022] Fourth, when extracting the active ingredients from honeysuckle and maca, they are compounded in specific ratios to enhance synergy. Cellulase is used to fully hydrolyze the plant cell walls, releasing more active ingredients. A dual enzymatic hydrolysis method using ficin and papain is employed to obtain specific small-molecule peptides, enhancing the synergistic efficacy of skin repair. The hydrolysis product is purified using HPD722 macroporous adsorption resin, utilizing the resin's varying adsorption capacities for different ingredients to remove substances that may irritate the skin. By optimizing these enzymatic hydrolysis and purification parameters, the extract's anti-inflammatory and repair-promoting activities are maximized, providing strong support for skin damage repair.

[0023] 5. Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion complex can improve the stability of Centella asiatica, release it gradually and slowly, stably and effectively inhibit the synthesis of melanin, and reduce skin pigmentation.

[0024] 6. Dipotassium glycyrrhizate, with its unique carboxyl group and potassium ion in its molecular structure, interacts synergistically with the active ingredients in Astragalus membranaceus extract. This synergistic effect forms a protective layer on the surface of red blood cell membranes, enhancing cell membrane stability and reducing the risk of red blood cell rupture under the influence of the drug, further enhancing drug safety.

[0025] 7. Liposome-encapsulated Panax notoginseng saponins-RGD peptides continuously release active ingredients, activating intracellular proliferation signaling pathways and promoting cell mitosis. The functional peptides in the honeysuckle-maca extract modulate the inflammatory response, attracting macrophages and fibroblasts to the site of injury, providing the necessary cellular foundation for wound repair. These two synergistically accelerate angiogenesis, delivering sufficient nutrients to the injured area, while also promoting epithelial cell migration and wound coverage, significantly enhancing wound healing efficiency.

[0026] 8. Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion complex inhibits tyrosinase activity, blocking melanin production at a key enzyme involved in melanin synthesis. Simultaneously, active substances in roasted astragalus extract and honeysuckle-maca extract modulate the function of immune cells such as macrophages, reducing the release of melanin-stimulating factors. These multiple ingredients work synergistically, inhibiting enzyme activity and regulating the immune system to prevent pigmentation, achieving a dual synergistic effect of "promoting healing and inhibiting pigmentation."

[0027] 9. Synergistic Proportions: The proportions of each ingredient in the drug have been carefully designed. For example, the mass fractions of the roasted astragalus extract, liposome-encapsulated ingredients, and honeysuckle-maca extract are strictly controlled within specific ranges. This precise ratio control avoids competitive inhibition or adverse interactions between the ingredients. For example, an inappropriate ratio of chlorogenic acid and asiaticoside can compete for the same target, resulting in reduced efficacy. A reasonable ratio ensures that each ingredient can fully exert its own efficacy, synergizing rather than canceling out each other, thereby maximizing the drug's overall efficacy. DETAILED DESCRIPTION

[0028] The present invention will be further described below with reference to specific implementation cases, but the present invention is not limited to these embodiments.

[0029] Example 1 A medicine for promoting the repair and healing of skin damage comprises the following raw materials in parts by mass: 28 parts of roasted astragalus root extract, 13 parts of liposome-encapsulated Panax notoginseng total saponins-RGD peptide, 14 parts of honeysuckle-maca extract, 8 parts of asiaticaside-hydroxypropyl-β-cyclodextrin inclusion complex and 4 parts of dipotassium glycyrrhizate.

[0030] Among them, the preparation method of the roasted Astragalus extract includes: slicing Astragalus, moistening it with honey for 2.5 hours at a honey-drug mass ratio of 0.25:1, baking it at 95°C for 20 minutes, crushing it through a 50-mesh sieve, adding deionized water at a material-liquid mass ratio of 1:13, extracting it at 92°C for 2.5 hours, filtering to obtain a filtrate, concentrating it under reduced pressure at 62°C to 25% of the filtrate volume, adding ethanol to a final volume concentration of 68%, standing it at 5°C for 26 hours, centrifuging it at 8500 rpm for 18 minutes, taking the supernatant, concentrating it under reduced pressure at 62°C to 13% of the supernatant volume, loading it onto a Sephadex G-15 column, eluting 2.5BV with an 18% volume concentration of ethanol aqueous solution to remove impurities, eluting 3.5BV with a 60% volume concentration of ethanol aqueous solution (adjusting the pH value to 5.2 with acetic acid), collecting the eluate, concentrating it under reduced pressure at 62°C to remove ethanol, and freeze-drying to obtain the roasted Astragalus extract.

[0031] Among them, the preparation method of liposome-encapsulated Panax notoginseng total saponin-RGD peptide includes: preparing a solute according to a mass ratio of soybean lecithin: cholesterol = 4.5:1.2, dissolving it in anhydrous ethanol to a solute concentration of 48 mg / mL to obtain an organic phase; adding a mixture of Panax notoginseng total saponins and RGD peptide at a mass ratio of 9:4 to a pH 7.5 phosphate buffer solution to a concentration of 18 mg / mL to obtain an aqueous phase; injecting the organic phase into the aqueous phase at a volume ratio of organic phase: aqueous phase = 1:1.3, stirring at 700 rpm for 40 minutes, rotary evaporation at 58°C to remove ethanol, obtaining a concentrated solution, 200W probe ultrasonication for 10 minutes, adding trehalose to a final concentration of 6wt% in the concentrated solution, and freeze-drying to obtain liposome-encapsulated Panax notoginseng total saponin-RGD peptide.

[0032] The preparation method of honeysuckle-maca extract includes: mixing honeysuckle dry powder and maca root dry powder passed through a 50-mesh sieve in a mass ratio of 4:1.3 to obtain a mixed powder; adding deionized water 10 times the mass of the mixed powder, adjusting the pH to 5.2 with acetic acid, adding 0.8% cellulase by mass of the mixed powder, enzymolysis at 58°C for 2.5h, adjusting the pH to 6.8 with dilute alkali, adding 0.8% ficin and papain by mass of the mixed powder, and enzymolysis at 58°C for 2.5h; heating Extract at 82℃ for 2.5h, centrifuge at 8500rpm for 18min to obtain the supernatant, concentrate at 62℃ under reduced pressure to 25% of the supernatant volume to obtain the concentrate, load it onto the HPD722 macroporous adsorption resin column, rinse 2.5BV with water to remove impurities, rinse 1.5BV with 32% concentrated ethanol aqueous solution to remove impurities, elute 4BV with 62% volume concentration ethanol aqueous solution, collect the eluate, concentrate at 62℃ under reduced pressure to remove ethanol, and freeze-dry to obtain the honeysuckle-maca extract.

[0033] Among them, the preparation method of Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion complex includes: preparing a mixture of Centella asiatica and hydroxypropyl-β-cyclodextrin in a mass ratio of 1:2.3, dissolving the mixture in a 32% volume concentration of ethanol aqueous solution to a mixture concentration of 12 mg / mL, ultrasonicating at 23°C and 350W probe for 50 minutes, refrigerating at 5°C for 14 hours, and freeze-drying to obtain the Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion complex.

[0034] Example 2 A medicine for promoting the repair and healing of skin damage comprises the following raw materials in parts by mass: 25 parts of roasted astragalus root extract, 15 parts of liposome-encapsulated Panax notoginseng total saponins-RGD peptide, 12 parts of honeysuckle-maca extract, 10 parts of asiaticoside-hydroxypropyl-β-cyclodextrin inclusion complex and 3 parts of dipotassium glycyrrhizate.

[0035] Among them, the preparation method of the roasted astragalus extract includes: slicing astragalus, moistening it with honey for 2 hours at a honey-drug mass ratio of 0.3:1, baking it at 100°C for 15 minutes, crushing it through a 60-mesh sieve, adding deionized water at a material-liquid mass ratio of 1:12, extracting it at 95°C for 2 hours, filtering to obtain a filtrate, concentrating it under reduced pressure at 65°C to 20% of the volume of the filtrate, adding ethanol to a final volume concentration of 70%, standing it at 4°C for 30 hours, centrifuging it at 8000 rpm for 20 minutes, taking the supernatant, concentrating it under reduced pressure at 60°C to 15% of the volume of the supernatant, loading it onto a Sephadex G-15 column, eluting 3BV with a 15% volume concentration of ethanol aqueous solution to remove impurities, eluting 3BV with a 50% volume concentration of ethanol aqueous solution (using acetic acid to adjust the pH to 5.5), collecting the eluate, concentrating it under reduced pressure at 65°C to remove ethanol, and freeze-drying to obtain the roasted astragalus extract.

[0036] Among them, the preparation method of liposome-encapsulated Panax notoginseng total saponin-RGD peptide includes: preparing a solute according to a mass ratio of soybean lecithin: cholesterol = 4:1.5, dissolving it in anhydrous ethanol to a solute concentration of 45 mg / mL to obtain an organic phase; adding a mixture of Panax notoginseng total saponins and RGD peptide at a mass ratio of 10:3 to a pH 7.6 phosphate buffer solution to a concentration of 15 mg / mL to obtain an aqueous phase; injecting the organic phase into the aqueous phase at a volume ratio of organic phase: aqueous phase = 1:1.5, stirring at 800 rpm for 30 minutes, rotary evaporation at 60°C to remove ethanol, obtaining a concentrated solution, 200W probe ultrasonication for 12 minutes, adding trehalose to a final concentration of 5wt% in the concentrated solution, and freeze-drying to obtain liposome-encapsulated Panax notoginseng total saponin-RGD peptide.

[0037] Among them, the preparation method of honeysuckle-maca extract includes: mixing honeysuckle dry powder and maca root dry powder passed through a 60-mesh sieve in a mass ratio of 3:1.7 to obtain a mixed powder; adding deionized water 8 times the mass of the mixed powder, adjusting the pH to 5.5 with acetic acid, adding 0.5% cellulase by mass of the mixed powder, enzymatically hydrolyzing at 60°C for 2h, adjusting the pH to 7.0 with dilute alkali, adding 0.5% ficin and papain by mass of the mixed powder, and enzymatically hydrolyzing at 60°C for 2h; heating to 85°C for extraction for 2h, centrifuging at 9000rpm for 15min to obtain a supernatant, concentrating at 65°C under reduced pressure to 20% of the volume of the supernatant to obtain a concentrated solution, loading the solution onto an HPD722 macroporous adsorption resin column, eluting 3BV with water to remove impurities, eluting 2BV with a 30% volume concentrated ethanol aqueous solution to remove impurities, eluting 5BV with a 60% volume concentration ethanol aqueous solution, collecting the eluate, concentrating under reduced pressure at 60°C to remove ethanol, and freeze-drying to obtain a honeysuckle-maca extract.

[0038] Among them, the preparation method of Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion complex includes: preparing a mixture of Centella asiatica and hydroxypropyl-β-cyclodextrin in a mass ratio of 1:2.5, dissolving the mixture in a 30% volume concentration of ethanol aqueous solution to a mixture concentration of 15 mg / mL, ultrasonicating at 20°C and 400W probe for 40 minutes, refrigerating at 6°C for 12 hours, and freeze-drying to obtain the Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion complex.

[0039] Example 3 A medicine for promoting the repair and healing of skin damage comprises the following raw materials in parts by mass: 30 parts of roasted astragalus root extract, 11 parts of liposome-encapsulated Panax notoginseng total saponins-RGD peptide, 15 parts of honeysuckle-maca extract, 6 parts of asiaticoside-hydroxypropyl-β-cyclodextrin inclusion complex and 5 parts of dipotassium glycyrrhizate.

[0040] Among them, the preparation method of the roasted astragalus extract includes: slicing astragalus, moistening it with honey for 3 hours at a honey-drug mass ratio of 0.2:1, baking it at 90°C for 25 minutes, crushing it through a 40-mesh sieve, adding deionized water at a material-liquid mass ratio of 1:15, extracting it at 90°C for 3 hours, filtering to obtain a filtrate, concentrating it under reduced pressure at 60°C to 30% of the volume of the filtrate, adding ethanol to a final volume concentration of 65%, standing it at 6°C for 24 hours, centrifuging it at 9000rpm for 15 minutes, taking the supernatant, concentrating it under reduced pressure at 65°C to 10% of the volume of the supernatant, loading it onto a Sephadex G-15 column, eluting it with a 20% volume concentration of ethanol aqueous solution for 2BV to remove impurities, eluting it with a 70% volume concentration of ethanol aqueous solution (adjusting the pH value to 5.0 with acetic acid) for 4BV, collecting the eluate, concentrating it under reduced pressure at 60°C to remove ethanol, and freeze-drying it to obtain the roasted astragalus extract.

[0041] Among them, the preparation method of liposome-encapsulated Panax notoginseng total saponin-RGD peptide includes: preparing a solute according to a mass ratio of soybean lecithin: cholesterol = 5:1, dissolving it in anhydrous ethanol to a solute concentration of 50 mg / mL to obtain an organic phase; adding a mixture of Panax notoginseng total saponins and RGD peptide at a mass ratio of 8:5 to a pH 7.4 phosphate buffer solution to a concentration of 20 mg / mL to obtain an aqueous phase; injecting the organic phase into the aqueous phase at a volume ratio of organic phase: aqueous phase = 1:1, stirring at 600 rpm for 50 minutes, rotary evaporation at 55°C to remove ethanol, obtaining a concentrated solution, ultrasonicating with a 250W probe for 8 minutes, adding trehalose to a final concentration of 8wt% in the concentrated solution, and freeze-drying to obtain liposome-encapsulated Panax notoginseng total saponin-RGD peptide.

[0042] Among them, the preparation method of honeysuckle-maca extract includes: mixing honeysuckle dry powder and maca root dry powder passed through a 40-mesh sieve in a mass ratio of 5:1 to obtain a mixed powder; adding deionized water 12 times the mass of the mixed powder, adjusting the pH to 5.0 with acetic acid, adding 1% cellulase by mass of the mixed powder, enzymatically hydrolyzing at 55°C for 3 hours, adjusting the pH to 6.5 with dilute alkali, adding 1% ficin and papain by mass of the mixed powder, and enzymatically hydrolyzing at 55°C for 3 hours; heating to 80°C for extraction for 3 hours, centrifuging at 8000 rpm for 20 minutes to obtain a supernatant, concentrating at 60°C under reduced pressure to 30% of the volume of the supernatant to obtain a concentrated solution, loading the solution onto an HPD722 macroporous adsorption resin column, eluting 2BV with water to remove impurities, eluting 1BV with a 35% volume concentrated ethanol aqueous solution to remove impurities, eluting 3BV with a 65% volume concentration ethanol aqueous solution, collecting the eluate, concentrating at 65°C under reduced pressure to remove ethanol, and freeze-drying to obtain a honeysuckle-maca extract.

[0043] Among them, the preparation method of Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion complex includes: preparing a mixture of Centella asiatica and hydroxypropyl-β-cyclodextrin in a mass ratio of 1:2, dissolving the mixture in a 35% volume concentration ethanol aqueous solution to a mixture concentration of 10 mg / mL, ultrasonicating at 25°C and 350W probe for 60 minutes, refrigerating at 4°C for 16 hours, and freeze-drying to obtain the Centella asiatica-hydroxypropyl-β-cyclodextrin inclusion complex.

[0044] The preparation method of a drug for promoting the repair and healing of skin damage in each of the above embodiments comprises the following steps: uniformly mixing the roasted astragalus extract, liposome-encapsulated Panax notoginseng total saponins-RGD peptide, honeysuckle-maca extract, asiatica sideroside-hydroxypropyl-β-cyclodextrin inclusion complex and dipotassium glycyrrhizate according to the mass parts of the raw materials in each embodiment to obtain a mixed drug.

[0045] The mixed drugs prepared in the above embodiments are formulated with pharmaceutically acceptable excipients to obtain dressings for promoting the repair and healing of skin injuries.

[0046] Comparative Example 1 The difference from Example 1 is that the amount of the roasted astragalus extract is changed to 14 parts, and the amount of the honeysuckle-maca extract is changed to 28 parts.

[0047] Comparative Example 2 The difference from Example 1 is that the amount of the roasted Astragalus root extract is changed to 13 parts, and the amount of the liposome-encapsulated Panax notoginseng total saponins-RGD peptide is changed to 28 parts.

[0048] Comparative Example 3 The difference from Example 1 is that: the amount of asiaticoside-hydroxypropyl-β-cyclodextrin inclusion complex is changed to 4 parts; and the amount of dipotassium glycyrrhizate is changed to 8 parts.

[0049] Comparative Example 4 The difference from Example 1 is that in the preparation method of the roasted astragalus extract, the astragalus is not moistened with honey and roasted; the astragalus is directly crushed and extracted with water.

[0050] Comparative Example 5 The difference from Example 1 is that in the preparation method of the roasted Astragalus extract, Sephadex G-15 is replaced by Sephadex LH-20.

[0051] Comparative Example 6 The difference from Example 1 is that in the preparation method of liposome-encapsulated Panax notoginseng total saponins-RGD peptide, the mass ratio of Panax notoginseng total saponins to RGD peptide is modified to 4:9.

[0052] Comparative Example 7 The difference from Example 1 is that in the preparation method of the honeysuckle-maca extract, the mass ratio of honeysuckle dry powder to maca root dry powder is modified to 1.3:4.

[0053] Comparative Example 8 The difference from Example 1 is that in the preparation method of the honeysuckle-maca extract, no ficin is added.

[0054] Comparative Example 9 The difference from Example 1 is that in the preparation method of the honeysuckle-maca extract, papain is replaced by bromelain.

[0055] Comparative Example 10 The difference from Example 1 is that in the preparation method of the honeysuckle-maca extract, ficin is replaced by bromelain.

[0056] Comparative Example 11 The difference from Example 1 is that in the preparation method of the honeysuckle-maca extract, the HPD722 macroporous adsorption resin column is replaced by D101 macroporous adsorption resin.

[0057] Comparative Example 12 The difference from Example 1 is that the roasted Astragalus extract is changed to 14 parts, the honeysuckle-maca extract is changed to 28 parts, the asiaticoside-hydroxypropyl-β-cyclodextrin inclusion complex is changed to 4 parts, the dipotassium glycyrrhizate is changed to 8 parts, the mass ratio of Panax notoginseng total saponins and RGD peptide is changed to 4:9, and the mass ratio of honeysuckle dry powder to maca root dry powder is changed to 1.3:4.

[0058] The raw material sources of the above-mentioned examples and comparative examples are as follows: Sephadex G-15 is from Shanghai Yuanye Biotechnology Co., Ltd., model S14030. Soybean lecithin is from Zhengzhou Wanruida Chemical Product Co., Ltd., pharmaceutical grade. Cholesterol is from Beijing Dingguo Changsheng Biotechnology Co., Ltd., pharmaceutical grade. Trehalose is from Xi'an Laviva Biotechnology Co., Ltd., pharmaceutical grade. Panax notoginseng saponins are from Wuhan Fengzhulin Chemical Technology Co., Ltd., raw medicinal materials. Cellulase is from Hefei Shengrun Biological Product Co., Ltd., enzyme activity 100,000 U / g. Ficus carica protease is from Hanzhong Hansuoyuan Biotechnology Co., Ltd., enzyme activity 100,000 U / g. Papain is from Sichuan Huatang Juerui Biotechnology Co., Ltd., enzyme activity 100,000 U / g. HPD722 macroporous adsorption resin is from Shanghai Yuanye Biotechnology Co., Ltd., model S25180. Centella asiatica glycoside is from Hanzhong Hansuoyuan Biotechnology Co., Ltd., pharmaceutical grade. Hydroxypropyl-β-cyclodextrin is from Shandong Zhonghuanzhongjie Biotechnology Co., Ltd., pharmaceutical grade. RGD peptide is arginine-glycine-aspartic acid peptide, which is from Chengdu Yunxi Chemical Co., Ltd., pharmaceutical intermediate. Glycyrrhizic acid dipotassium is from Jiangsu Aolisi Pharmaceutical Co., Ltd., pharmaceutical grade. Dextran gel LH-20 is from Shanghai Yuanye Biotechnology Co., Ltd., model S14037. D101 macroporous adsorption resin is from Shanghai Yuanye Biotechnology Co., Ltd., model S14161. Bromelain is from Shaanxi Hohua Beikang Biotechnology Co., Ltd., enzyme activity 100,000 U / g.

[0059] 1. Safety detection: 1.1 Hemolysis detection: Sample preparation: 10 mg of mixed drug powder was taken and placed in a centrifuge tube, 1.0 mL of PBS (pH 7.4) was added, vortexed for 10 min, filtered with a 0.22 μm filter membrane, centrifuged at 3000 rpm for 10 min (4°C), and the supernatant was taken and diluted with PBS to a gradient concentration of 0.5 mg / mL, 1 mg / mL, 2 mg / mL and 4 mg / mL.

[0060] Method steps: healthy human anticoagulated blood (EDTA anticoagulation) was taken and washed with normal saline for 3 times (each time at 4°C, 1500 rpm centrifugation for 10 min), and the red blood cells were prepared into a 2% (v / v) suspension with normal saline.

[0061] Reaction system:

[0062] The experimental group was set up with 3 replicates. After 2h in a 37℃ water bath, centrifugation was performed at 1500rpm for 10min (4℃), and the supernatant was taken to measure the absorbance value A at 540nm. Hemolysis rate% = (A experimental group - A negative control) / (A positive control - A negative control) x 100%. Hemolysis rate < 5% is safe. The test results are shown in Table 1 below.

[0063] Table 1 Hemolysis test results (hemolysis rate% interval, 3 replicate samples)

[0064] 1.2 Sensitization (h-CLAT) test: Sample preparation: Drug stock solution: 10mg / mL (RPMI 1640 medium containing 0.1% DMSO); Working solution: diluted to 50μg / mL, 100μg / mL (filtered and sterilized) with RPMI 1640 medium containing 10% FBS.

[0065] Solvent control: RPMI 1640 medium containing 0.1% DMSO; Positive control: 1mM NiSO4.

[0066] Method steps: THP-1 cells were inoculated in 24-well plates at 1×10 6 cells / mL (RPMI 1640 + 10% FBS) at 1mL / well. The 24-well plates were placed in a cell incubator at 37℃, 5% CO2 saturated humidity for 24h; centrifugation (1500rpm x 5min, 4℃), discard the supernatant, and the cells were washed once with PBS. Add 1mL / well of different concentrations of working solution (experimental group), solvent control, positive control, respectively, and set up 3 replicates for the experimental group. Continue to culture for 24 hours. Collect cells: transfer the cell suspension to a flow tube. Centrifuge at 1500rpm for 5min (4℃), discard the supernatant, and wash the cells with PBS twice (add 1mL PBS each time, centrifuge and discard the supernatant). Resuspend the cells with 100μL PBS. Add fluorescently labeled antibodies: 5μL anti-human CD86-FITC, 5μL anti-human CD54-PE, avoid light, ice bath for 30min. Wash the cells with PBS twice (add 1mL PBS each time, centrifuge and discard the supernatant). Resuspend the cells with 300μL PBS, and detect by flow cytometry. RFI (CD86) ≥ 150% and RFI (CD54) ≥ 200%, or RFI (CD86) ≥ 200% and RFI (CD54) ≥ 150%, are determined as positive; otherwise, it is determined as negative (no sensitization). The test results are shown in Table 2 below.

[0067] Table 2 Sensitization test results (RFI interval%, 3 replicates)

[0068] 2. Efficacy detection: 2.1 Cell proliferation detection (CCK-8 method): Sample preparation: drug solution 100 μg / mL (0.9% physiological saline preparation, filter sterilization).

[0069] Detection method: human epidermal keratinocytes were inoculated in 96-well plates at a density of 3×10 4 cells / well (100 μL DMEM+10%FPS), and incubated in a cell incubator at 37°C, 5% CO2 saturated humidity for 24 h to adhere, then the old culture medium was discarded, and 100 μL of drug solution was added.

[0070] Control group was set up at the same time:

[0071] Each group had 5 replicate wells (experimental group), and the culture was continued for 48 h, the culture medium was discarded, and 100 μL of new culture medium containing 10% CCK-8 was added to each well, and the incubation was continued for 2 h in the dark. The absorbance OD value was measured at 450 nm wavelength, and the cell proliferation rate (%) = (experimental group OD value-drug background control group OD value-blank group OD value) / (negative control group OD value-blank group OD value)×100%. The detection results are shown in Table 3.

[0072] Table 3 Cell proliferation detection results (proliferation rate% interval, 5 replicate wells)

[0073] 2.2 Melanin synthesis inhibition detection: Sample preparation: drug stock solution: 10 mg / mL (DMEM base medium containing 0.1% DMSO); working solution: diluted to 100 μg / mL with DMEM base medium containing 10% FBS (filter sterilization).

[0074] Control group was set up:

[0075] Method steps: B16F10 cells were inoculated in 96-well plates at a density of 5×10 4The cells were inoculated in 96-well plates at 100 μL / well, and were incubated in a cell incubator at 37°C, 5% CO2, and saturated humidity for 24 h to adhere to the wall; the old culture medium was removed; 100 μL of a working solution containing 100 nM α-MSH was added (5 replicates were set), and a control group was set up, and the incubation was continued for 48 h; the culture solution was removed; PBS was used for washing once; 100 μL of 1 mol / L NaOH solution (containing 10% DMSO) was added to each well, and was incubated at 80°C for 1 h (melanin was dissolved); the absorbance OD value was measured at 405 nm by using an enzyme-labeled instrument. The melanin synthesis inhibition rate (%) = [1- (OD drug group-OD unstimulated group) / (α-MSH stimulated group-OD unstimulated group)] x 100%; each value was deducted from the background value of the blank group. The test results are shown in Table 4.

[0076] In this test, the ΔOD of the α-MSH stimulation group and the OD unstimulated group = OD solvent control group-OD unstimulated group; ΔOD > 0.5, and the stimulation is effective.

[0077] Table 4: Melanin synthesis inhibition test results (inhibition rate % interval, 5 replicates)

[0078] In Examples 1 to 3, the honey processed and Sephadex G-15 purified Astragalus membranaceus extract removes the sensitizing impurities and retains the components for enhancing the stability of the red blood cell membrane, and cooperates with dipotassium glycyrrhizinate to reduce the rupture of red blood cells. The liposome encapsulated total notoginseng saponins-RGD peptide is isolated from immune cells by the phospholipid bilayer, avoids triggering an immune response, and the sustained release feature of the liposome can continuously release the active ingredients to provide a stable signal for cell proliferation. The Honeysuckle-Maca extract is purified by double enzymolysis (cellulase + ficin + papain) and HPD722 resin, which can remove tannins and other stimulants and retain functional ingredients, including functional small molecule peptides; the asiaticoside-hydroxypropyl-β-cyclodextrin inclusion compound stabilizes the structure by the hydrophobic cavity of the cyclodextrin, inhibits the activity of tyrosinase, and cooperates with other ingredients to play a role in inhibiting melanin synthesis.

[0079] Comparative Example 1 (reduced Astragalus membranaceus and increased Honeysuckle-Maca): The Astragalus membranaceus extract is reduced, and the membrane stabilizing components (such as astragalus saponins) contained therein are insufficient, and the protective effect on the red blood cell membrane is weakened; the Honeysuckle-Maca extract is excessive, and excessive chlorogenic acid can bind with the phospholipid of the red blood cell membrane to destroy the membrane structure. The excessive Honeysuckle-Maca extract contains excessive macromolecular sensitizing impurities that are not removed, which easily triggers an immune response; at the same time, chlorogenic acid competes with asiaticoside to bind to the target, reducing the melanin inhibition effect.

[0080] Comparative Example 2 (less roasted Astragalus root, more liposome-encapsulated Panax notoginseng total saponins-RGD peptide): Insufficient roasted Astragalus root negates its protective effect on erythrocyte membranes; excessive liposomes increase the osmotic pressure of the solution, causing erythrocyte shrinkage and rupture. Excessive liposome-encapsulated Panax notoginseng total saponins-RGD peptide is easily recognized by immune cells, triggering an immune response. Furthermore, excessive amounts of these ingredients interfere with normal cellular physiological processes and affect cell proliferation signaling.

[0081] Comparative Example 3 (reduced asiaticoside-hydroxypropyl-β-cyclodextrin inclusion complex and increased dipotassium glycyrrhizate): Excessive dipotassium glycyrrhizate interferes with normal cellular physiological functions and affects red blood cell membrane stability. Decreased asiaticoside reduces the inhibitory effect on melanin synthesis; excessive dipotassium glycyrrhizate affects the synergistic effects of other ingredients and interferes with cell proliferation signaling pathways.

[0082] Comparative Example 4 (Roasted Astragalus Extract Not Honey-Rubbed and Toasted): The types and content of active ingredients in the roasted Astragalus were altered without honey-rubbed and toasted, making it less effective in maintaining red blood cell membrane stability. Untreated Astragalus extract retains more allergenic impurities, potentially triggering an immune response. This alteration in active ingredients also compromises its ability to promote cell proliferation and inhibit melanin synthesis.

[0083] Comparative Example 5 (Sephadex G-15 replaced with Sephadex LH-20): Different gels have different separation selectivities for extract components. The composition of the Astragalus membranaceus extract separated using Sephadex LH-20 changes, affecting its synergistic effect with other components in protecting red blood cell membranes. This change in extract composition leads to an increase in residual allergenic components, triggering a stronger immune response. Furthermore, the shift in the proportion of active ingredients affects cell proliferation and melanin inhibition.

[0084] Comparative Example 6 (change in the mass ratio of Panax notoginseng total saponins and RGD peptide): Changes in the ratio affect the liposome encapsulation effect and the release of active ingredients, and change the effect of the drug on the red blood cell membrane; improper ratios affect the stability of the liposome structure and stimulate immune cells; at the same time, an imbalance in the ratio of active ingredients will interfere with cell proliferation signals and the melanin inhibition process.

[0085] Comparative Example 7 (Altered Honeysuckle and Maca Ratio): Changing the raw material ratio alters the extract's composition and activity, affecting its synergistic effect with other ingredients in maintaining red blood cell membrane stability. This altered extract composition leads to an increase in allergens, triggering an immune response. Furthermore, the altered ratio of active ingredients affects anti-inflammatory effects and melanin inhibition, further impacting cell proliferation.

[0086] Comparative Example 8 (Honeysuckle-Maca Extract without Ficin): The absence of ficin impairs enzymatic hydrolysis and extraction of components in the extract, altering the peptide sequence of the final extract and affecting hemolysis. Inadequate enzymatic hydrolysis results in residual allergens, triggering an immune response. Furthermore, the extract contains fewer active ingredients, reducing its effectiveness in promoting cell proliferation and inhibiting melanin synthesis.

[0087] Comparative Example 9 (Papain replaced with bromelain): Different proteases react with different substrates and have different effects. Substituting bromelain for papain altered the composition and activity of the peptide extract, affecting hemolysis. This change in extract composition can introduce new allergens, triggering an immune response. Furthermore, changes in the active ingredients can affect cell proliferation signaling and melanin inhibition.

[0088] Comparative Example 10 (ficin replaced with bromelain): Replacing ficin with bromelain altered the extract's composition, affecting its synergistic effect with other ingredients in maintaining red blood cell membrane stability. The extract also contained an increase in allergenic components, triggering a stronger immune response. Furthermore, the shift in the ratio of active ingredients affected cell proliferation and melanin inhibition.

[0089] Comparative Example 11 (HPD722 macroporous adsorption resin replaced with D101): Different resins have varying adsorption and elution capacities for extract components. Using D101 macroporous adsorption resin alters the composition of the extract, affecting hemolysis. This leaves more allergenic components in the extract, triggering an immune response. Furthermore, the loss of active ingredients reduces the effects of promoting cell proliferation and inhibiting melanin synthesis.

[0090] Comparative Example 12 (Multiple Factor Changes): The alterations in the ratios and composition of multiple raw materials severely disrupted the formulation balance. The ingredients failed to synergize to maintain red blood cell membrane stability, significantly increasing their destructive effects. This disrupted formulation increased allergens, triggering an immune response. Furthermore, the synergistic effects between the ingredients were disrupted, significantly reducing the inhibitory effects on cell proliferation and melanin.

Claims

1. A drug for promoting the repair and healing of skin damage, characterized in that: The drug comprises the following raw materials in parts by weight: 25 to 30 parts of roasted astragalus root extract, 11 to 15 parts of liposome-encapsulated Panax notoginseng total saponins-RGD peptide, 12 to 15 parts of honeysuckle-maca extract, 6 to 10 parts of asiaticaside-hydroxypropyl-β-cyclodextrin inclusion complex and 3 to 5 parts of dipotassium glycyrrhizate; The astragalus root extract is obtained by soaking astragalus root in honey, baking it, extracting it with deionized water, and purifying it by adsorption on a Sephadex G-15 column. In the liposome-encapsulated Panax notoginseng total saponins-RGD peptide, the mass ratio of Panax notoginseng total saponins to RGD peptide is (8-10): (3-5); The honeysuckle-maca extract is a product obtained by mixing honeysuckle dry powder and maca root dry powder in a mass ratio of (3-5): (1-1.7), hydrolyzing with cellulase, and then hydrolyzing with ficin and papain together, and then purifying the product by adsorption on an HPD722 macroporous adsorption resin column.

2. A drug for promoting skin damage repair and healing according to claim 1, characterized in that: The preparation method of the roasted astragalus extract comprises the following steps: slicing astragalus root, moistening it with honey at a honey-drug mass ratio of (0.2-0.3):1, baking it, crushing it, adding deionized water at a material-liquid mass ratio of 1:(12-15), extracting it at 90°C-95°C, filtering it to obtain a filtrate, concentrating it under reduced pressure to 20%-30% of the volume of the filtrate, adding ethanol to a final volume concentration of 65%-70%, allowing it to stand, centrifuging it, collecting the supernatant, concentrating it under reduced pressure to 10%-15% of the volume of the supernatant, loading it onto a Sephadex G-15 column, eluting it with a 15%-20% volume concentration ethanol aqueous solution for 2BV-3BV to remove impurities, eluting it with a 50%-70% volume concentration ethanol aqueous solution for 3BV-4BV, collecting the eluate, concentrating it under reduced pressure to remove ethanol, and freeze-drying it to obtain the roasted astragalus extract.

3. A drug for promoting skin damage repair and healing according to claim 2, characterized in that: In the preparation method of roasted astragalus extract, the honey penetration time is 2h to 3h; the baking is at 90℃ to 100℃ for 15min to 25min; the crushing particle size is passed through a 40-mesh to 60-mesh sieve; the extraction time is 2h to 3h; the standing is at 4℃ to 6℃ for 24h to 30h; the centrifugation is at 8000rpm to 9000rpm for 15min to 20min; the 50% to 70% volume concentration ethanol aqueous solution is adjusted to a pH value of 5.0 to 5.5 using acetic acid; and the temperature of the reduced pressure concentration is 60℃ to 65℃.

4. A drug for promoting the repair and healing of skin damage according to claim 1, characterized in that: The preparation method of the liposome-encapsulated Panax notoginseng total saponin-RGD peptide comprises: preparing a solute according to a mass ratio of soybean lecithin: cholesterol = (4-5): (1-1.5), dissolving the solute in anhydrous ethanol to a solute concentration of 45 mg / mL-50 mg / mL, to obtain an organic phase; adding a mixture of Panax notoginseng total saponins and RGD peptide according to a mass ratio of (8-10): (3-5) to a phosphate buffer solution to a concentration of 15 mg / mL-20 mg / mL, to obtain an aqueous phase; injecting the organic phase into the aqueous phase according to a volume ratio of organic phase: aqueous phase = 1: (1-1.5), stirring, rotary evaporation to remove ethanol, obtaining a concentrated solution, probe sonication, adding trehalose, and freeze-drying to obtain the liposome-encapsulated Panax notoginseng total saponin-RGD peptide.

5. A drug for promoting the repair and healing of skin damage according to claim 4, characterized in that: In the preparation method of liposome-encapsulated Panax notoginseng total saponin-RGD peptide, the pH of the phosphate buffer solution is 7.4-7.6; the organic phase is injected into the aqueous phase at 55°C-60°C; the stirring is 600rpm-800rpm for 30min-50min; the temperature of the rotary evaporation is 55°C-60°C; the probe ultrasound is 200W-250W probe ultrasound for 8min-12min; and the amount of trehalose added is trehalose to a final concentration of 5wt%-8wt% of the concentrated solution.

6. The drug for promoting the repair and healing of skin damage according to claim 1, characterized in that: The preparation method of the honeysuckle-maca extract comprises: mixing honeysuckle dry powder and maca root dry powder in a mass ratio of (3-5): (1-1.7) to obtain a mixed powder; adding deionized water, adjusting the pH to 5.0-5.5 with acetic acid, adding cellulase, performing enzymatic hydrolysis at 55-60°C for 2-3 hours, adjusting the pH to 6.5-7.0 with dilute alkali, adding ficin and papain, performing enzymatic hydrolysis at 55-60°C for 2-3 hours; and heating extraction. Centrifuge to obtain a supernatant, concentrate under reduced pressure to 20% to 30% of the volume of the supernatant to obtain a concentrated solution, load it onto an HPD722 macroporous adsorption resin column, rinse 2BV to 3BV with water to remove impurities, rinse 1BV to 2BV with a 30% to 35% volume concentrated ethanol aqueous solution to remove impurities, elute 3BV to 5BV with a 60% to 65% volume concentration ethanol aqueous solution, collect the eluate, concentrate under reduced pressure to remove ethanol, and freeze-dry to obtain the honeysuckle-maca extract.

7. A drug for promoting the repair and healing of skin damage according to claim 6, characterized in that: In the preparation method of honeysuckle-maca extract, the particle size of the honeysuckle dry powder and the maca root dry powder are both sieved through a 40-mesh to 60-mesh sieve; the amount of deionized water used is 8 to 12 times the mass of the mixed powder; the amount of cellulase added is 0.5% to 1% of the mass of the mixed powder; the amount of ficin and papain added is both 0.5% to 1% of the mass of the mixed powder; the heating extraction is heating to 80°C to 85°C for extraction for 2h to 3h; the centrifugation is centrifuged at 8000rpm to 9000rpm for 15min to 20min; and the temperature of the reduced pressure concentration is 60°C to 65°C.

8. The drug for promoting the repair and healing of skin damage according to claim 1, characterized in that: The preparation method of the asiaticoside-hydroxypropyl-β-cyclodextrin inclusion complex comprises: preparing a mixture of asiaticoside and hydroxypropyl-β-cyclodextrin in a mass ratio of 1:(2-2.5), dissolving the mixture in an ethanol aqueous solution to a concentration of 10 mg / mL-15 mg / mL, performing probe sonication, refrigerating, and freeze-drying to obtain the asiaticoside-hydroxypropyl-β-cyclodextrin inclusion complex.

9. The drug for promoting the repair and healing of skin damage according to claim 8, characterized in that: In the preparation method of the Centella asiatica glycoside-hydroxypropyl-β-cyclodextrin inclusion complex, the ethanol aqueous solution is an ethanol aqueous solution with a volume concentration of 30% to 35%; the probe ultrasound is 20°C to 25°C, 350W to 400W probe ultrasound for 40min to 60min; and the refrigeration is 4°C to 6°C for 12h to 16h.

10. The method for preparing a drug for promoting the repair and healing of skin damage according to claim 1, characterized in that: The preparation method comprises the following steps: uniformly mixing, according to parts by mass, roasted astragalus root extract, liposome-encapsulated Panax notoginseng total saponins-RGD peptide, honeysuckle-maca extract, asiaticoside-hydroxypropyl-β-cyclodextrin inclusion complex and dipotassium glycyrrhizate to obtain a mixed medicine.

Images